NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 156 filers reported holding NEVRO CORP in Q2 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,282,644 | +203.5% | 118,764 | +301.4% | 0.01% | +100.0% |
| Q2 2023 | $752,051 | -80.5% | 29,585 | -72.2% | 0.00% | -94.8% |
| Q1 2023 | $3,849,830 | +279.9% | 106,496 | +316.2% | 0.06% | +222.2% |
| Q4 2022 | $1,013,285 | +273.9% | 25,588 | +339.7% | 0.02% | +260.0% |
| Q3 2022 | $271,000 | -71.0% | 5,819 | -72.7% | 0.01% | -80.8% |
| Q2 2022 | $933,000 | +46.0% | 21,291 | +140.9% | 0.03% | +52.9% |
| Q1 2022 | $639,000 | -37.5% | 8,838 | -29.9% | 0.02% | -46.9% |
| Q4 2021 | $1,022,000 | +129.1% | 12,609 | +229.4% | 0.03% | +146.2% |
| Q3 2021 | $446,000 | +89.0% | 3,828 | +125.6% | 0.01% | -50.0% |
| Q3 2020 | $236,000 | -36.4% | 1,697 | -60.6% | 0.03% | +13.0% |
| Q3 2019 | $371,000 | -10.8% | 4,310 | -32.9% | 0.02% | -50.0% |
| Q2 2019 | $416,000 | +96.2% | 6,420 | +72.8% | 0.05% | -53.5% |
| Q3 2018 | $212,000 | – | 3,716 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 622,615 | $38,920,000 | 8.04% |
| Tamarack Advisers, LP | 160,000 | $10,002,000 | 3.97% |
| Birch Run Capital Advisors, LP | 187,425 | $11,716,000 | 3.72% |
| Prosight Management, LP | 128,765 | $8,049,000 | 3.52% |
| Ratan Capital Management LP | 38,653 | $2,416,000 | 3.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 579,463 | $36,222,000 | 1.39% |
| Spark Investment Management LLC | 403,400 | $25,216,000 | 1.17% |
| Sivik Global Healthcare LLC | 50,000 | $3,126,000 | 1.15% |
| ArrowMark Colorado Holdings LLC | 1,882,009 | $117,644,000 | 1.11% |
| PFM Health Sciences, LP | 721,229 | $45,084,000 | 1.00% |